Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905228 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 study of Glioblastoma and Solid Tumors, sponsored by Incuron.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 4
- Study locations
NCT01905228 is a Phase 1 study of Glioblastoma and Solid Tumors that has completed, run by Incuron. The registered enrollment target is 83 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (23% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT01905228, a Phase 1 study of Glioblastoma and Solid Tumors, has completed, sponsored by Incuron.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
Conditions Studied
Interventions
- DRUG CBL0137
Study Locations (4)
Ohio
- University Hospital of Cleveland - Cleveland
- Cleveland Clinic - Cleveland
New York
- Roswell Park Cancer Institute - Buffalo
Texas
- CTRC at The University of Texas Healh Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01905228
The ClinicalTrials.gov registry entry for NCT01905228 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (23% lower). The listed sponsor is Incuron, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which CBL0137 is the first listed.
NCT01905228 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT01905228 about?
NCT01905228 is a clinical study titled "A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm". This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
What is the current status of trial NCT01905228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2013-07. Estimated completion is 2019-06.
What conditions does trial NCT01905228 study?
This clinical trial studies the following conditions: Glioblastoma, Solid Tumors.
What interventions are being tested in trial NCT01905228?
The interventions under investigation include: CBL0137 (DRUG).
Who is sponsoring clinical trial NCT01905228?
This trial is sponsored by Incuron, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01905228 being conducted?
This trial has 4 study locations across New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.